The KLHL22 Knockout A-549 Polyclonal Cells constitute a CRISPR/Cas9-edited polyclonal knockout population targeting the KLHL22 gene in the A-549 human lung adenocarcinoma cell line. As a pooled loss-of-function model, this product retains genetic diversity, circumventing clonal selection artifacts and providing a robust system for mechanistic studies of KLHL22 in a physiologically relevant cancer background.
The A-549 host cell line is a hypotriploid epithelial model with a modal chromosome number of 66, derived from an explanted lung carcinoma of a 58-year-old Caucasian male. Widely used for alveolar epithelial biology and non-small-cell lung cancer research, A-549 cells exhibit characteristics of type II pneumocytes, including surfactant expression and barrier function, making them a fitting context for studying lung adenocarcinoma-associated pathways.
KLHL22 acts as a substrate adaptor for the CUL3-RBX1 E3 ubiquitin ligase complex, directing ubiquitination and proteasomal degradation of specific targets. Under amino acid sufficiency, it promotes degradation of DEPDC5, a GATOR1 complex component, thereby releasing inhibition of Rag GTPases and activating mTORC1 signaling to drive cell growth. KLHL22 also mediates degradation of ??-catenin, reducing Wnt pathway transcriptional output via LEF/TCF. Thus, KLHL22 disruption stabilizes both DEPDC5 and ??-catenin, attenuating mTORC1 activity while potentially enhancing oncogenic ??-catenin signals in A-549 cells.
In the A-549 lung adenocarcinoma background, the KLHL22 knockout model enables examination of its putative tumor-suppressive role. Accumulated ??-catenin may promote migration, invasion, and proliferation, while DEPDC5-mediated mTORC1 suppression could sensitize cells to mTOR inhibitors. The polyclonal population also facilitates study of how viral factors, such as Epstein-Barr virus proteins, co-opt KLHL22-dependent ubiquitination to alter host signaling, offering insights into infection-driven malignancy.
Typical applications include western blotting for KLHL22, DEPDC5, and phospho-S6K1; co-immunoprecipitation to assess CUL3 interaction; and ubiquitination assays to monitor substrate modification. The knockout cells support functional assays such as proliferation, apoptosis, and migration/invasion, as well as drug sensitivity testing with mTOR inhibitors. Researchers can also employ RT-qPCR and immunofluorescence for expression and localization studies. For additional information, please contact Ascent Research.
